Anti-MRSA agent 28 

Anti-MRSA agent 28 is an antibacterial agent against multidrug resistant (MDR) gram-positive strains with MICs of 0.06-0.125 μg/mL. Anti-MRSA agent 28 can target DNA polymerase IIIC to reduce the amount of genomic DNA with the IC₅₀ of 3.80 μg/mL. Anti-MRSA agent 28 has good antibacterial activity and reduces inflammation. Anti-MRSA agent 28 can be used against gram-positive strains and infectious conditions^[1].

Anti-MRSA agent 28 (Compound 5a) shows antibacterial activity against the Gram-positive strains, including S. aureus ATCC 33591 (MIC = 0.125 μg/mL), ATCC 700698 (MIC = 0.125 μg/mL), ATCC 700699 (MIC = 0.06 μg/mL) and ATCC BAA1708 (MIC = 0.125 μg/mL) ^[1].

Anti-MRSA agent 28 (0.25 μg/mL-4 μg/mL; 0 h-24 h) has antibacterial activity against S. aureus ATCC 33591^[1].

Anti-MRSA agent 28 (1 μg/mL; 1 h) might inhibit the dysfunction of genomic DNA^[1].

Anti-MRSA agent 28 (0.5 μg/mL-4.5 μg/mL) effectively influence the quantity of genomic DNA^[1].

Anti-MRSA agent 28 (6.25 μM-50 μM) can dose-dependently bond to immobilized DNA Pol IIIC with the K_D of 8.45 μM^[1].

Anti-MRSA agent 28 (0 μg/mL-16 μg/mL) inhibits the DNA Pol IIIC of S. aureus ATCC 33591^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-MRSA agent 28 (2 % in vaseline; once daily; for 3 days) significantly reduces the number of bacteria and lowers systemic inflammation, while effectively alleviating necrosis of infected tissues and infiltration and accumulation of neutrophils^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

503.93

C₂₇H₂₂ClN₃O₅

2222727-47-9

COC1=C(C2=C(C3=C4C5=C(C6=C(OCO6)C=C5CC[N+]4=C2)C=C3)C=C1)OC(C7=CC(C)=NN7C)=O.[Cl-]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fan T, et al. Evolution of 8-esterified cycloberberines as a novel class of antibacterial agents against MDR gram-positive strains by targeting DNA polymerase IIIC. Bioorg Chem. 2025 May 28;163:108640.  [Content Brief]